May 12, 2020Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity™ m System- Alinity m is Abbott's new molecular lab system, which was approved by the U.S. FDA in March- The Alinity m system is highly advanced and greatly improves speed and efficiency, running up to 1,080 tests in 24 hours- Abbott is launching Alinity m to U.S. customers and will be making the SARS-CoV-2 test available for use under an Emergency Use Authorization- This is Abbott's fifth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic- May 11, 2020- Data shows reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days after symptoms began- Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT and Alinity i platforms and will have capacity for 60 million in June- Abbott expects to submit for CE Mark for its Alinity i SARS-CoV-2 IgG test this week and will initiate global shipments immediately- This is Abbott's fourth COVID-19 test to receive FDA EUA, helping to provide hospitals and labs across the U.S. with broad, reliable molecular and antibody testing during this pandemic
- May 8, 2020- Researchers found the test to have 99.9% specificity and 100% sensitivity for patients tested 17 days or more after symptoms began- More than 10 million ARCHITECT antibody tests already have been shipped to hospitals and labs around the world
Apr 27, 2020-- New authorization from Health Canada allows FreeStyle Libre system to be used by frontline healthcare workers in hospitals to remotely monitor patients' glucose status to minimize exposure during COVID-19 and preserve use of personal protective equipment (PPE)-- Abbott will donate 3,000 FreeStyle Libre sensors to Canadian hospitals in need to help accelerate access to technology- Apr 16, 2020- First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent- Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19)